Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry

Spekhorst, Lotte S; Ariëns, Lieneke F.M.; Schaft, Jorien van der; Bakker, Daphne; Kamsteeg, Marijke; Oosting, A. J.; Ridder, Ilona de; Sloeserwij, Annemiek; Romeijn, Geertruida L E; Graaf, Marlies de; Haeck, Inge; Thijs, Judith L.; Schuttelaar, Marie L A; Bruin‐Weller, Marjolein S. de

doi:10.1111/all.14324

Cited by 31 publications

(37 citation statements)

References 8 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding systemic drug survival, our findings are in reasonable agreement with previous studies. Likewise, reasons for discontinuation are also comparable with those found in the literature 1–3,7,8 . Considering survival analysis as a reflection of the performance of a drug in daily practice, the results for dupilumab in our study demonstrate a clear superiority in terms of persistence compared with systemic therapy.…”

Section: Figuresupporting

confidence: 87%

“…Recently, dupilumab, a fully human monoclonal antibody that targets the interleukin‐4 receptor α, has been approved for the treatment of moderate‐to‐severe AD. Although its efficacy and effectiveness have been reported in previous clinical trials 4 and real‐world evidence publications, 5,6 the drug survival analyses of dupilumab have, to date, been limited 7,8 …”

Section: Figurementioning

confidence: 99%

See 1 more Smart Citation

Drug survival of systemic and biological treatments for moderate‐to‐severe atopic dermatitis in adults: a multicentre retrospective observational study

et al. 2020

View full text Add to dashboard Cite

Section: Figuresupporting

confidence: 87%

Section: Figurementioning

confidence: 99%

Drug survival of systemic and biological treatments for moderate‐to‐severe atopic dermatitis in adults: a multicentre retrospective observational study

et al. 2020

View full text Add to dashboard Cite

“…In EUROSTAD, which started before the TREAT consensus was published, Peak Pruritus NRS were collected weekly, however, other measures were collected every 3 months, without the initial 4-weekly follow-ups (43). The demographic and clinical characteristics of EUROSTAD participants were generally aligned with those in BIODAY, another prospective multicenter registry (44,45). Compared with BIODAY, EUROSTAD participants had slightly lower baseline EASI scores.…”

Section: Discussionmentioning

confidence: 99%

Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study

Bruin‐Weller

Pink

Patrizi

et al. 2021

Journal of Dermatological Treatment

Self Cite

View full text Add to dashboard Cite

Background: Insights into the real-world treatment paradigm and long-term burden of atopic dermatitis (AD) are needed to inform clinical and health policy decisions. Methods: The prospective, observational EUROSTAD study enrolled adults with moderate-to-severe AD starting or switching systemic therapy (51 sites in 10 European countries). We report the baseline characteristics, treatment patterns, and outcomes of these patients using descriptive statistics. Results: A 12-month enrollment period of EUROSTAD was completed and 308 patients were enrolled: average age 37 years, AD duration 25 years, 43% were female. Most patients reported use of systemic therapy (93%) and !1 atopic comorbidity (82%). Mean [standard deviation] disease severity/burden measures were high: Investigator's Global Assessment (3.1 [0.8]), Eczema Area and Severity Index (16.2 [10.9]), Peak Pruritus Numerical Rating Scale (5.5 [2.5]), sleep impairment Visual Analog Scale (49.8 [31.6]) scores, and time lost from work (4.1 [13.7] days/year) or usual activities (16.8 [38.7] days/year). Most patients showed borderline or clinical levels of anxiety (59%) and/or depression (63%) using the Hospital Anxiety and Depression Scale. Conclusions: Adults with moderate-to-severe AD starting/switching systemic treatment enrolled in EUROSTAD have a high burden of longstanding disease despite continuous use of topical drugs, emollients, and systemic therapies.

show abstract

“…Drug survival is a comprehensive outcome covering effectiveness, safety, patients', and doctors' preferences. Drug survival studies comparing dupilumab with other conventional oral immunosuppressive drugs including CsA for AD are scarce 11,12 . The objective of this study was to investigate drug survival of dupilumab in comparison with CsA, reasons of drug discontinuation, and predictive parameters of drug survival.…”

Section: Introductionmentioning

confidence: 99%

Drug survival of dupilumab compared to cyclosporin in moderate‐to‐severe atopic dermatitis patients

Bello

Maurelli

Schena

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Dupilumab and cyclosporin are recommended treatments for moderate-to-severe atopic dermatitis (AD). The objective of this study was to investigate drug survival of dupilumab in comparison with CsA, reasons of drug discontinuation, and predictive parameters of drug survival in daily practice. Retrospective study including patients with moderate-to-severe AD treated with dupilumab or cyclosporin (CsA) from January 1, 2019 to April 30, 2020. Drug survival analysis was performed using the Kaplan-Meier method and predictive factors were analyzed using multivariate Cox regression analyses. Adult patients with AD (n = 251) treated with dupilumab (n = 149) or CsA (n = 102) were included. Sixteen months from baseline, 82% of patients receiving dupilumab were still on treatment vs 11% of those treated with CsA. Reason for withdrawing dupilumab were primary inefficacy in 4.7% of patients, persistent clinical remission in 7.4%, and cutaneous adverse effects in 2.0%. Older age at diagnosis and shorter AD duration predicted shorter dupilumab survival. Reasons for CsA withdrawal included adverse effects in 23.5% of patients, persistent clinical remission in 15.6%, and a minimal or absent improvement in 11.7%. Dupilumab has a longer drug survival compared to CsA. Only a limited number of dupilumab patients discontinued treatment due to adverse effects and/or ineffectiveness.

show abstract

Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry

Abstract: Human alveolar macrophage responses to air pollution particulates are associated with insoluble components of coarse material, including particulate endotoxin .

Cited by 31 publications

References 8 publications

Drug survival of systemic and biological treatments for moderate‐to‐severe atopic dermatitis in adults: a multicentre retrospective observational study

Drug survival of systemic and biological treatments for moderate‐to‐severe atopic dermatitis in adults: a multicentre retrospective observational study

Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study

Drug survival of dupilumab compared to cyclosporin in moderate‐to‐severe atopic dermatitis patients

Contact Info

Product

Resources

About